Antibiotic proteins of polymorphonuclear leukocytes

European Journal of Haematology

Volumn 56, Issue 5, 1996, Pages 263-277

  Levy, Ofer ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antmicrobial proteins and peptides; Granulocyte; Innate immunity; LPS; Neutrophil

Indexed keywords

ANTIBIOTIC AGENT; ANTIBIOTIC PEPTIDE; ANTIBIOTIC PROTEIN; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; HUMAN; HUMAN CELL; INFLAMMATION; NEUTROPHIL; PRIORITY JOURNAL; REVIEW;

EID: 0030012702     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb00714.x     Document Type: Review

References (177)

1. HOFFMANN JA, JANEWAY CA, NATORI S, eds. Phylogenetic Perspectives in Immunity: The insect host defense. Boca Raton: CRC Press: 1994.
2. CHANOCK SJ, BANNA J, SMITH RM, BABIOR BM. The respiratory burst oxidase. J Biol Chem 1994: 269: 24519-24522.
3. NATHAN CF. Natural resistance and nitric oxide. Cell 1995: 82: 873-876.
4. MOORE KS, WEHRLI S, RODER H, et al. Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci USA 1993: 90: 1354-1358.
5. ELSBACH P, WEISS J. Oxygen-independent antimicrobial systems of phagocytes. In: GALLIN JI, GOLDSTEIN IM, SNYDERMAN R, eds. Inflammation: Basic principles and clinical correlates. New York: Raven Press: 1992: 603-636.
6. BOMAN HG. Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 1995: 13: 61-92.
7. GALLIN JI. Disorders of phagocytic cells. In: GALLIN JI, GOLDSTEIN IM, SNYDERMAN R, eds. Inflammation: Basic principles and clinical correlates. New York: Raven Press: 1992: 859-874.
8. METCHNIKOFF E. Lectures on the Comparative Pathology of Inflammation. New York: Dover Publications: 1968 (reprint).
9. BUCHNER H. Neuere fortschritte in der immunitatsfrage. Munch med Wochschr 1894: 41: 497-500.
10. DENYS J, HAVET J. Pouvoir bactericide du sange de chien. La Cellule 1894: 10: 7-35.
11. BALDRIDGE CW, GERARD RW. The extra respiration of phagocytosis. Am J Physiol 1933: 103: 235-236.
12. 2-independent killing of Gram-negative bacteria by intact granulocytes: the role of a potent bactericidal membrane-perturbing protein. Adv Exp Med Biol 1982: 141: 129-137.
13. MALAWISTA SE, MONTGOMERY RR, VAN BLARICUM G. Evidence for reactive nitrogen intermediates in killing of staphylococci by human neutrophil cytoplasts: a new microbicidal pathway for polymorphonuclear leukocytes. J Clin Invest 1992: 90: 631-636.
14. FLEMING A. On a remarkable bacteriolytic element found in tissues and excretions. Proc Roy Soc (London) 1922: 93: 306-310.
15. HIRSCH JG. Phagocytin: a bactericidal substance from polymorphonuclear leukocytes. J Exp Med 1956: 103: 589-621.
16. ZEYA HI, SPITZNAGEL JK. Antibacterial and enzymic basic proteins from leukocyte lysosomes: separation and identification. Science 1963: 142: 1085-1087.
17. MÜLLER-EBERHARD HJ. Complement: chemistry and pathways. In: GALLIN JI, GOLDSTEIN IM, SNYDERMAN R, eds. Inflammation: Basic principles and clinical correlates. New York: Raven Press: 1992: 33-62.
18. BOTTO M, LISSANDRINI D, SORIO C, WALPORT MJ. Biosynthesis and secretion of complement component (C3) by activated human polymorphonuclear leukocytes. J Immunol 1992: 149: 1348-1355.
19. HOGASEN AKM, WURZNER R, ABRAHAMSEN TG, DIERICH MP. Human polymorphonuclear leukocytes store large amounts of terminal complement components C7 and C6, which may be released on stimulation. J Immunol 1994: 154: 4734-4740.
20. ELLISON RT. The effects of lactoferrin on Gram-negative bacteria. In: HUTCHENS TW, RUMBALL SV, LONNERDAL B. eds. Lactoferrin: Structure and function. Advances in experimental medicine & biology, vol. 357. New York: Plenum Press: 1994: 357: 71-90.
21. OLSSON I, LANTZ, M, PERSSON AM, ARNLJOTS K. Biosynthesis and processing of lactoferrin in bone marrow cells, a comparison with processing of myeloperoxidase. Blood 1988: 71: 441-447.
22. BORREGAARD N, SEHESTED M, NIELSEN BS, SENGELOV H, KJELDSEN L. Biosynthesis of granule proteins in normal human bone marrow cells: gelatinase is a marker of terminal neutrophil differentiation. Blood 1995: 85: 812-817.
23. ANDERSON BF, BAKER HM, DODSON EJ, et al. Structure of human lactoferrin at 3.2-Å resolution. Proc Natl Acad Sci USA 1987: 84: 1769-1773.
24. PETTERSSON A, MAAS A, TOMMASSEN J. Identification of the iroA gene product of Neisseria meningtidis as a lactoferrin receptor. J Bacteriol 1994: 176: 1764-1766.
25. ARNOLD RR, RUSSELL JE, CHAMPION WJ, BREWER M. Bactericidal activity of human lactoferrin: differentiation from stasis of iron deprivation. Infect Immun 1982: 35: 792-799.
26. YAMAUCHI K, TOMITA M, GIEHL TJ, ELLISON RT. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun 1993: 61: 719-728.
27. APPELMELK BJ, AN Y, GEERTS M, et al. Lactoferrin is a lipid A-binding protein. Infect Immun 1994: 62: 2628-2632.
28. WANG D, PABST KM, AIDA Y, PABST MJ. Lipopolysaccharide-inactivating activity of neutrophils is due to lactoferrin. J Leuk Biol 1995: 57: 865-874.
29. HARMSEN MC, SWART PJ, BETHUNE MD, et al. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 1995: 172: 380-388.
30. SHAU H, KIM A, GOLUB SH. Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin. J Leuk Biol 1992: 51: 343-349.
31. BROXMEYER HE, PLATZER E. Lactoferrin acts on 1-A and I-E/C antigen+subpopulations of mouse peritoneal macrophages in the absence of T lymphocytes and other cell types to inhibit production of granulocyte-macrophage colony stimulatory factors in vitro. J Immunol 1984: 133: 306-314.
32. KUROSE I, YAMADA T, WOLF R, GRANGER DN. P-selectin-dependent leukocyte recruitment and intestinal mucosal injury induced by lactoferrin. J Leuk Biol 1994: 55: 771-777.
33. MEILINGER M, HAUMER M, SZAKMARY KA, et al. Removal of lactoferrin from plasma is mediated by binding to low density lipoprotein receptor-related protein/∝-2-macroglobulin receptor and transport to endosomes. FEBS Lett 1995: 360: 70-74.
34. HURLEY WL, HEGARTY HM, METZLER JT. In vitro inhibition of mammary cell growth by lactoferrin: a comparative study. Life Sci 1994: 55: 1955-1962.
35. HE J, FURMANSKI P. Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 1995: 373: 721-724.
36. ELSBACH P, PETTIS P, BECKERDITE S, FRANSON R. Effects of phagocytosis by rabbit granulocytes on macromolecular synthesis and degradation in different species of bacteria. J Bact 1973: 115: 490-497.
37. WEISS J, ELSBACH P, OLSSON I, ODEBERG H. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem 1978: 253: 2664-2672.
38. ELSBACH P, WEISS J. The bactericidal/permeability-increasing protein (BPI), a potent element in host-defense against Gram-negative bacteria and lipopolysaccharide. Immunobiol 1993: 187: 417-429.
39. 2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. J Biol Chem 1987: 262: 14891-14894.
40. LEVY O, OOI CE, WEISS J, LEHRER RI, ELSBACH P. Individual and synergistic effects of rabbit granulocyte proteins on Escherichia coli. J Clin Invest 1994: 94: 672-682.
41. OPAL SM, PALARDY JE, MARRA MN, FISHER CJ, MCKELLIGON BM, SCOTT RW. Relative concentrations of endotoxin-binding proteins in body fluids during infection. Lancet 1994: 344: 429-431.
42. WEINRAUCH Y, FOREMAN A, SHU C, et al. Extracellular accumulation of potently microbicidal bactericidal permeability-increasing protein and p15s in an evolving sterile rabbit peritoneal inflammatory exudate. J Clin Invest 1995: 95: 1916-1924.
43. WEERSINK AJ, VAN KESSEL KP, VAN DEN TOL ME, et al. Human granulocytes express a 55-kDa lipopolysaccharide-binding protein on the cell surface that is identical to the bactericidal permeability-increasing protein. J Immunol 1993: 150: 253-263.
44. ZHAO MH, JONES SJ, LOCKWOOD CM. Bactericidal permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol 1995: 99: 49-56.
45. KALLENBERG CGM, BROUWER E, MULDER AHL, STEGEMAN CA, WEENING JJ, COHEN-TERVAERT JW. ANCA-pathophysiology revisited. Clin Exp Immunol 1995: 100: 1-3.
46. WEISS J, MUELLO K, VICTOR M, ELSBACH P. The role of lipopolysaccharides in the action of the bactericidal permeability-increasing neutrophil protein on the bacterial envelope. J Immunol 1984: 132: 3109-3115.
47. MANNION BA, WEISS J, ELSBACH P. Separation of sublethal and lethal effects of the bactericidal permeability increasing protein on Escherichia coli. J Clin Invest 1990: 85: 853-860.
48. ELSBACH P, WEISS J, LEVY O. Integration of antimicrobial host defenses: role of the bactericidal permeability-increasing protein. Trends Microbiol 1994: 2: 324-328.
49. GAZZANO-SANTORO H, PARENT JB, GRINNA L, et al. High-affinity binding of the bactericidal permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun 1992: 60: 4754-4761.
50. 2-terminal fragment cause killing of serum-resistant Gramnegative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin Invest 1992: 90: 1122-1130.
51. MARRA MN, WILDE CG, GRIFFITH JE, SNABLE JL, SCOTT RW. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol 1990: 144: 662-666.
52. TOBIAS PS, ULEVITCH RJ. Lipopolysaccharide-binding protein and CD14 in the lipopolysaccharide-dependent activation of cells. Chest 1994: 105: 485-505.
53. GAZZANO-SANTORO H, MESZAROS K, BIRR C, et al. Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and Gram-negative bacteria. Infect Immun 1994: 62: 1185-1191.
54. WILDE CG, SEILHAMER JJ, MCGROGAN M, et al. Bactericidal/permeability-increasing protein and lipopolysaccharide (LPS) binding protein: LPS binding properties and effects on LPS-mediated cell activation. J Biol Chem 1994: 269: 17411-17416.
55. LEVY O, OOI CE, ELSBACH P, DOERFLER ME, LEHRER RI, WEISS J. Antibacterial proteins of granulocytes differ in interaction with endotoxin: comparison of bactericidal permeability-increasing protein, p15s, and defensins. J Immunol 1995: 154: 5403-5410.
56. AMMONS WS, KOHN FR, KUNG AHC. Protective effects of an N-terminal fragment of bactericidal permeability-increasing protein in rodent models of Gram-negative sepsis: role of bactericidal properties. J Infect Dis 1994: 170: 1473-1482.
57. ELSBACH P, WEISS J. Prospects for the use of recombinant BPI in the treatment of Gram-negative bacterial infections. Infect Agents Dis 1995: 4: 102-109.
58. VON DER MÖHLEN MAM, KIMMINGS AN, WEDEL NI, et al. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal permeability-increasing protein. J Infect Dis 1995: 172: 144-151.
59. VON DER MÖHLEN MAM, VAN DEVENTER SJH, LEVI M, et al. Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI23). Blood 1995: 85: 3437-3443.
60. GABAY JE, ALMEIDA RP. Antibiotic peptides and serine protease homologs in human polymorphonuclear leukocytes: defensins and azurocidin. Curr Opin Immunol 1993: 5: 97-102.
61. PEREIRA HA. CAP37, a neutrophil-derived multifunctional inflammatory mediator. J Leuk Biol 1995: 57: 805-812.
62. MCGUIRE MJ, LIPSKY PE, THIELE DL. Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl peptidase I. J Biol Chem 1993: 268: 2458-2467.
63. LINDMARK A, GULLBERG U, OLSSON I. Processing and intracellular transport of Cathepsin G and neutrophil elastase in the leukemic myeloid cell line U-937: modulation by brefeldin A, ammonium chloride, and monensin. J Leuk Biol 1994: 55: 50-57.
64. AMERIK AY, YAROVOI SV, GRIGORENKO VG, ANTONOV VK. Identification, sequence analysis, and characterization of cDNA clones encoding two granzyme-like serine proteinases from rat duodenum. FEBS Lett 1993: 324: 226-230.
65. ZIMMER M, MEDCALF RL, FINK TM, MATTMANN C, LICHTER P, JENNE DE. Three human elastase-like genes coordinately expressed in the myelomonocyte lineage are organized as a single genetic locus on 19pter. Proc Natl Acad Sci USA 1992: 89: 8215-8219.
66. CAMPANELLI D, DETMERS PA, NATHAN CF, GABAY JE. Azurocidin and a homologous serine protease from neutrophils. Differential antimicrobial and proteolytic properties. J Clin Invest 1990: 85: 904-915.
67. BANGALORE N, TRAVIS J, ONUNKA VC, POHL J, SHAFER WM. Identification of the primary antimicrobial domains in human neutrophil Cathepsin G. J Biol Chem 1990: 265: 13584-13588.
68. PEREIRA HA, ERDEM I, POHL J, SPITZNAGEL JK. Synthetic bactericidal peptide based on CAP37: a 37-kDa human neutrophil granule-associated cationic antimicrobial protein chemotactic for monocytes. Proc Natl Acad Sci USA 1993: 90: 4733-4737.
69. LOMAS DA, STONE SR, LLEWELLYN-JONES C, et al. The control of neutrophil chemotaxis by inhibitors of cathepsin G and chymotrypsin. J Biol Chem 1995: 270: 23437-23443.
70. OWEN CA, CAMPBELL MA, SANNES PL, BOUKEDES SS, CAMPBELL EJ. Cell surface-bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases. J Cell Biol 1995: 131: 775-789.
71. ERMOLIEFF J, BOUDIER C, LAINE A, MEYER B, BIETH JG. Heparin protects Cathepsin G against inhibition by protein proteinase inhibitors. J Biol Chem 1994: 269: 29502-29508.
72. KUSNER DJ, KINO CH. Protease-modulation of neutrophil Superoxide response. J Immunol 1989: 143: 1696-1702.
73. PEREIRA HA, SCHAFER WM, POHL J, MARTIN LE, SPITZNAGEL JK. CAP37, a human neutrophil-derived chemotactic factor with monocyte specific activity. J Clin Invest 1990: 85: 1468-1476.
74. OSTERGAARD E, FLODGAARD H. A neutrophil-derived proteolytic inactive elastase homologue (hHBP) mediates reversible contraction of fibroblasts and endothelial cell monolayers and stimulates monocyte survival and thrombospondin secretion. J Leuk Biol 1992: 51: 316-323.
75. RENESTO P, HALBWACHS-MECARELLI L, NUSBAUM P, LESAVRE P, CHIGNARD M. Proteinase 3: a neutrophil proteinase with activity on platelets. J Immunol 1994: 152: 4612-4617.
76. KURDOWSKA A, TRAVIS J. Acute phase protein stimulation by α1-antichymotrypsin-cathepsin G complexes. J Biol Chem 1990: 265: 21023-21026.
77. BORIES D, RAYNAL M, SOLOMON DH, DARZYNKIEWICZ Z, CAYRE YE. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 1989: 59: 959-968.
78. TRAPANI JA SM, APOSTOLIDIS VA, DAWSON M, BROWNE KA. Granule serine proteases are normal nuclear constituents of natural killer cells. J Biol Chem 1994: 269: 18359-18365.
79. ZANETTI M, GENNARO R, ROMEO D. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 1995: 374: 1-5.
80. LENARCIC B, RITONJA A, DOLENC I, et al. Pig leukocyte cysteine proteinase inhibitor (PLCPI), a new member of the stefin family. FEBS Lett 1993: 336: 289-292.
81. ZHAO C, GANZ T, LEHRER RI. The structure of porcine protegrin genes. FEBS Lett 1995: 368: 197-202.
82. KOKRYAKOV VN, HARWIG SS, PANYUTICH EA, et al. Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett 1993: 327: 231-236.
83. STORICI P, ZANETTI M. A cDNA derived from pig bone marrow cells predicts a sequence identical to the intestinal antibacterial peptide PR-39. Biochem Biophys Res Comm 1993: 196: 1058-1065.
84. GALLO RL, ONO M, POVSIC T, et al. Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc Natl Acad Sci USA 1994: 91: 11035-11039.
85. HARWIG SSL, KOKYAKOV VN, SWIDEREK KM, ALESHINA GM, ZHAO C, LEHRER RI. Prophenin-1, an exceptionally proline-rich antimicrobial peptide from porcine leukocytes. FEBS Lett 1995: 362: 65-69.
86. ZANETTI M, STORICI P, TOSSI A, SCOCCHI M, GENNARO R. Molecular cloning and chemical synthesis of a novel antibacterial peptide derived from pig myeloid cells. J Biol Chem 1994: 269: 7855-7858.
87. STORICI P, SCOCCHI M, TOSSI A, GENNARO R, ZANETTI M. Chemical synthesis and biological activity of a novel antibacterial peptide deduced from a pig myeloid cDNA. FEBS Lett 1994: 337: 303-307.
88. GUDMUNDSSON GH, MAGNUSSON KP, CHOWDHARY BP, JOHANSSON M, ANDERSSON L, BOMAN HG. Structure of the gene for porcine peptide antibiotic PR-39, a cathelin gene family member: comparative mapping of the locus of the human peptide antibiotic FALL-39. Proc Natl Acad Sci USA 1995: 92: 7085-7089.
89. ZHAO C, GANZ T, LEHRER RI. Structures of genes for two cathelin-associated antimicrobial peptides: prophenin-2 and PR-39. FEBS Lett (in press).
90. SCOCCHI M, SKERLAVAJ B, ROMEO D, GENNARO R. Proteolytic cleavage by neutrophil elastase converts inactive storage preforms to antibacterial bactenecins. Eur J Biochem 1992: 209: 589-595.
91. SKERLAVAJ B, ROMEO D, GENNARO R. Rapid membrane permeabilization and inhibition of vital functions of Gram-negative bacteria by bactenecins. Infect Immun 1990: 58: 3724-3730.
92. VERBANAC D, ZANETTI M, ROMEO D. Chemotactic and protease-inhibiting activities of antibiotic peptide precursors. FEBS Lett 1993: 317: 255-258.
93. STORICI P, DEL SG, SCHNEIDER C, ZANETTI M. cDNA sequence analysis of an antibiotic dodecapeptide from neutrophils. FEBS Lett 1992: 314: 187-190.
94. DEL SAL G, STORICI P, SCHNEIDER C, ROMEO D, ZANETTI M. cDNA cloning of the neutrophil bactericidal peptide indolicidin. Biochem Biophys Res Comm 1992: 187: 467-472.
95. HU B, COULSON L, MOYER B, PRICE PA. Isolation and molecular cloning of a novel bone phosphoprotein related in sequence to the cystatin family of thiol protease inhibitors. J Biol Chem 1995: 270: 431-436.
96. LARRICK JW, HIRATA M, ZHENG H, et al. A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. J Immunol 1994: 152: 231-240.
97. HIRATA M, SHIMOMURA Y, YOSHIDA M, et al. Characterization of a rabbit cationic protein (CAP18) with lipopolysaccharide-inhibitory activity. Infect Immun 1994: 62: 1421-1426.
98. LARRICK JW, HIRATA M, SHIMOMOURA Y, et al. Antimicrobial activity of rabbit CAP18-derived peptides. Antimicrob Agents Chemother 1993: 37: 2534-2539.
99. TOSSI A, SCOCCHI M, SKERLAVAJ B, GENNARO R. Identification and characterization of a primary antibacterial domain in CAP18, a lipopolysaccharide binding protein from rabbit leukocytes. FEBS Lett 1994: 339: 108-112.
100. CHEN C, BROCK R, LUH F, et al. The solution structure of the active domain of CAP18 - a lipopolysaccharide binding protein from rabbit leukocytes. FEBS Lett 1995: 370: 46-52.
101. LEVY O, WEISS J, ZAREMBER K, OOI CE, ELSBACH P. Antibacterial 15-kDa protein isoforms (p15s) are members of a novel family of leukocyte proteins. J Biol Chem 1993: 268: 6058-6063.
102. OOI CE, WEISS J, LEVY O, ELSBACH P. Isolation of two isoforms of a novel 15-kDa protein from rabbit polymorphonuclear leukocytes that modulate the antibacterial actions of other leukocyte proteins. J Biol Chem 1990: 265: 15956-15962.
103. ZANETTI M, LITTERI L, GRIFFITHS G, GENNARO R, ROMEO D. Stimulus-induced maturation of probactenecins, precursors of neutrophil antimicrobial polypeptides. J Immunol 1991: 146: 4295-4300.
104. BORREGAARD N, LOLLIKE K, KJELDSEN L, et al. Human neutrophil granules and secretory vesicles. Eur J Haem 1993: 51: 187-198.
105. AGERBERTH B, GUNNE H, ODEBERG J, KOGNER P, BOMAN HG, GUDMUNDSSON GH. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci USA 1995: 92: 195-199.
106. LARRICK JW, HIRATA M, BALINT RF, LEE J, ZHONG J, WRIGHT SC. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 1995: 63: 1291-1297.
107. COWLAND JB, JOHNSEN AH, BORREGAARD N. hCAP-18, a cathelin/probactenecin-like protein of human neutrophil specific granules. FEBS Lett 1995: 368: 173-176.
108. KOZIN F, COCHRANE CG. The contact activation system of plasma. In: GALLIN JI, GOLDSTEIN IM, SNYDERMAN R, eds. Inflammation: Basic principles and clinical correlates. New York: Raven Press: 1992: 112-113.
109. BARKER RL, GLEICH GJ, PEASE LR. Acidic precursor revealed in human eosinophil granule major basic protein cDNA. J Exp Med 1988: 168: 1493-1498.
110. LIU L, GANZ T. The pro region of human neutrophil defensin contains a motif that is essential for normal subcellular sorting. Blood 1995: 85: 1095-1103.
111. JOLLES P, JOLLES J. What's new in lysozyme research? Mol Cell Biochem 1984: 63: 165-189.
112. CHUNG LP, KESHAV S, GORDON S. Cloning of the human lysozyme cDNA: inverted Alu repeat in the mRNA and in situ hybridization for macrophages and Paneth cells. Proc Natl Acad Sci USA 1988: 85: 6227-6230.
113. TAKEUCHI K, IRWIN DM, GALLUP M. et al. Multiple cDNA sequences of bovine tracheal lysozyme. J Biol Chem 1993: 268: 27440-27446.
114. AHNE B, STRÄTLING WH. Characterization of a myeloid-specific enhancer of the chicken lysozyme gene. J Biol Chem 1994: 269: 17794-17801.
115. GOETHE R, VAN PHI L. The far upstream chicken lysozyme enhancer at -6.1 kilobase, by interacting with NF-M, mediates lipopolysaccharide-induced expression of the chicken lysozyme gene in chicken myelomonocytic cells. J Biol Chem 1994: 269: 31302-31309.
116. SELSTED ME, MARTINEZ RJ. Lysozyme: primary bactericidin in human plasma serum active against Bacillus subtilis. Infect Immun 1978: 20: 782-791.
117. JOHNSON KG. Effect of growth conditions on peptidoglycan structure and susceptibility to lytic enzymes in cell walls of Micrococcus sodonensis. Biochemistry 1972: 11: 277-286.
118. LAIBLE NJ, GERMAINE GR. Bactericidal activity of human lysozyme, muramidase-inactive lysozyme, and cationic polypeptides against Streptococcus sanguis and Streptococcus faecalis: inhibition by chitin oligosaccharides. Infect Immun 1985: 48: 720-728.
119. IBRAHIM HR, YAMADA M, MATSUSHITA K, KOBAYASHI K, KATO A. Enhanced bactericidal action of lysozyme to Escherichia coli by inserting a hydrophobic pentapeptide into its C terminus. J Biol Chem 1994: 269: 5059-5063.
120. OHNO N, MORRISON DC. Lipopolysaccharide interaction with lysozyme: binding of lipopolysaccharide to lysozyme and inhibition of lysozyme enzymatic activity. J Biol Chem 1989: 264: 4434-4441.
121. TAKADA K, OHNO N, YADOMAE T. Lysozyme regulates LPS-induced interleukin-6 release in mice. Circ Shock 1994: 44: 169-174.
122. 2. J Biol Chem 1994: 269: 13057-13060.
123. WRIGHT GC, WEISS J, KIM KS, VERHEIJ H, ELSBACH P. Bacterial phospholipid hydrolysis enhances the destruction of Escherichia coli ingested by rabbit neutrophils. Role of cellular and extracellular phospholipases. J Clin Invest 1990: 85: 1925-1935.
124. 2 on Escherichi coli exposed to the bactericidal/permeability-increasing protein of neutrophils. Biochim Biophys Acta 1987: 920: 221-225.
125. WEISS J, INADA M, ELSBACH P, CROWL RM. Structural determinants of the action against Escherichia coli of a human inflammatory fluid phospholipase A2 in concert with polymorphonuclear leukocytes. J Biol Chem 1994: 269: 26331-26337.
126. 2. J Clin Invest 1995: 95: 603-610.
127. 2. J Clin Invest 1996: 97: 250-257.
128. HESSIAN PA, EDGEWORTH J, HOGG N. MRP-8 and MRP-14, two abundant Ca2+-binding proteins of neutrophils and monocytes. J Leuk Biol 1993: 53: 197-204.
129. STEINBAKK M, NAESS AC, LINGAAS E, DALE I, BRANDTZAEG P, FAGERHOL MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990: 336: 763-765.
130. SOHNLE PG, COLLINS LC, WIESSNER JH. The zinc-reversible antimicrobial activity of neutrophil lysates and abscess fluid supernatants. J Infect Dis 1991: 164: 137-142.
131. COUTO MA, HARWIG SS, CULLOR JS, HUGHES JP, LEHRER RI. eNAP-2, a novel cysteine-rich bactericidal peptide from equine leukocytes. Infect Immun 1992: 60: 5042-5047.
132. DRENTH J, LOW BW, RICHARDSON JS, WRIGHT CS. The toxin-agglutinin fold: a new group of small protein structures organized around a four-disulfide core. J Biol Chem 1980: 255: 2652-2655.
133. SEEMULLER U, ARNHOLD M, FRITZ H, et al. The acid-stable proteinase inhibitor of human mucous secretions (HUSI-I, antileukoprotease). FEBS Lett 1986: 199: 43-48.
134. DANDEKAR AM, ROBINSON EA, APPELLA E, QASBA PK. Complete sequence analysis of cDNA clones encoding rat whey phosphoprotein: homology to a protease inhibitor. Proc Natl Acad Sci USA 1982: 79: 3987-3991.
135. MIRELMAN D, GALUN E, SHARON N, LOTAN R. Inhibition of fungal growth by wheat germ agglutinin. Nature 1975: 256: 414-416.
136. COUTO MA, HARWIG SS, LEHRER RI. Selective inhibition of microbial serine proteases by eNAP-2, an antimicrobial peptide from equine neutrophils. Infect Immun 1993: 61: 2991-2994.
137. BATEMAN A, BELCOURT D, BENNETT H, LAZURE C, SOLOMON S. Granulins, a novel class of peptide from leukocytes. Biochem Biophys Res Comm 1990: 173: 1161-1168.
138. SHOYAB M, MCDONALD VL, BYLES C, TODARO GJ, PLOWMAN GD. Epithelins 1 and 2: isolation and characterization of two cysteine-rich growth-modulating proteins. Proc Natl Acad Sci USA 1990: 87: 7912-7916.
139. COUTO MA, HARWIG SS, CULLOR JS, HUGHES JP, LEHRER RI. Identification of eNAP-1, an antimicrobial peptide from equine neutrophils. Infect Immun 1992: 60: 3065-3071.
140. BELCOURT DR, LAZURE C, BENNETT HP. Isolation and primary structure of the three major forms of granulin-like peptides from hematopoietic tissues of a teleost fish (Cyprinus carpio). J Biol Chem 1993: 268: 9230-9237.
141. BHANDARI V, PALFREE RG, BATEMAN A. Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains. Proc Natl Acad Sci USA 1992: 89: 1715-1719.
142. CULOUSCOU JM, CARLTON GW, SHOYAB M. Biochemical analysis of the epithelin receptor. J Biol Chem 1993: 268: 10458-10462.
143. MARTIN E, GANZ T, LEHRER RI. Defensins and other endogenous peptide antibiotics of vertebrates. J Leukoc Biol 1995: 58: 128-136.
144. HILL CP, YEE J, SELSTED ME, EISENBERG D. Crystal structure of defensin HNP-3, an amphiphilic dimer: mechanisms of membrane permeabilization. Science 1991: 251: 1481-1485.
145. GANZ T. Biosynthesis of defensins and other antimicrobial peptides. In: MARSH J, GOODE JA, eds. Antimicrobial Peptides. Ciba Foundation Symposium, vol. 186. New York: Wiley: 1994: 186: 62-76.
146. DIAMOND G, ZASLOFF M, ECK H, BRASSEUR M, MALOY WL, BEVINS CL. Tracheal antimicrobial peptide, a cysteine-rich peptide from mammalian tracheal mucosa: peptide isolation and cloning of a cDNA. Proc Natl Acad Sci USA 1991: 88: 3952-3956.
147. TANG YQ, SELSTED ME. Characterization of the disulfide motif in BNBD-12, an antimicrobial beta-defensin peptide from bovine neutrophils. J Biol Chem 1993: 268: 6649-6653.
148. LINZMEIER R, MICHAELSON D, LIU L, GANZ T. The structure of neutrophil defensin genes. FEBS Lett 1993: 321: 267-273.
149. HU J, JOTHY S, SOLOMON S. Localization and measurement of corticostatin-I in nonpregnant and pregnant rabbit tissues during late gestation. Endocrinology 1993: 132: 2351-2359.
150. OUELLETTE AJ, GRECO RM, JAMES M, FREDERICK D, NAFTILAN J, FALLON JT. Developmental regulation of cryptdin, a corticostatin/defensin precursor mRNA in mouse small intestinal crypt epithelium. J Cell Biol 1989: 108: 1687-1695.
151. EISENHAUER PB, HARWIG SS, LEHRER RI. Cryptdins: antimicrobial defensins of the murine small intestine. Infect Immun 1992: 60: 3556-3565.
152. JONES DE, BEVINS CL. Paneth cells of the human small intestine express an antimicrobial peptide gene. J Biol Chem 1992: 267: 23216-23225.
153. SCHONWETTER BS, STOLZENBERG ED, ZASLOFF MA. Epithelial antibiotics induced at sites of inflammation. Science 1995: 267: 1645-1648.
154. BENSCH KW, RAIDA M, MAGERT HJ, SCHULZ-KNAPPE P, FORSSMANN WG. hBD-1: a novel β-defensin from human plasma. FEBS Lett 1995: 368: 331-335.
155. DIAMOND G, JONES DE, BEVINS CL. Airway epithelial cells are the site of expression of a mammalian antimicrobial peptide gene. Proc Natl Acad Sci USA 1993: 90: 4596-4600.
156. SHIMODA M, OHKI K, SHIMAMOTO Y, KOHASHI O. Morphology of defensin-treated Staphlococcus aureus. Infect Immun 1995: 63: 2886-2891.
157. GROISMAN EA. How bacteria resist killing by host-defense peptides. Trends Micro 1995: 2: 444-449.
158. LICHTENSTEIN AK, GANZ T, SELSTED ME, LEHRER RI. Synergistic cytolysis mediated by hydrogen peroxide combined with peptide defensins. Cell Immunol 1988: 114: 104-116.
159. COUTO MA, LIU L, LEHRER RI, GANZ T. Inhibition of intracellular Histoplasma capsulatum replication by murine macrophages that produce human defensin. Infect Immun 1994: 62: 2375-2378.
160. PANYUTICH AV, PANYUTICH EA, KRAPIVIN VA, BATUREVICH EA, GANZ T. Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis. J Lab Clin Med 1993: 122: 202-207.
161. PANYUTICH AV, SZOLD O, POON PH, TSENG Y, GANZ T. Identification of defensin binding to C1 complement. FEBS Lett 1994: 356: 169-173.
162. GALLIN MY, JACOBI AB, BÜTTNER DW, SCHÖNBERGER Ö, MARTI T, ERTTMANN KD. Human autoantibody to defensin: disease association with hyperreactive onchocerciasis (Sowda). J Exp Med 1995: 182: 41-47.
163. TERRITO MC, GANZ T, SELSTED ME, LEHRER R. Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest 1989: 84: 2017-2020.
164. MACLEOD RJ, HAMILTON JR, BATEMAN A, et al. Corticostatic peptides cause nifedipine-sensitive volume reduction in jejunal villus enterocytes. Proc Natl Acad Sci USA 1991: 88: 552-556.
165. NYGAARD SD, GANZ T, PETERSON MW. Defensins reduce the barrier integrity of a cultured epithelial monolayer without cytotoxicity. Am J Respir Cell Mol Biol 1993: 8: 193-200.
166. MURPHY CJ, FOSTER BA, MANNIS MJ, SELSTED ME, REID TW. Defensins are mitogenic for epithelial cells and fibroblasts. J Cell Physiol 1993: 155: 408-413.
167. HIGAZI AA, BARGHOUTI II, ABU-MUCH R. Identification of an inhibitor of tissue-type plasminogen activator-mediated fibrinolysis in human neutrophils. J Biol Chem 1995: 270: 9472-9477.
168. PANYUTICH AV, HIEMSTRA PS, VAN WETERING S, GANZ T. Human neutrophil defensin and serpins form complexes and inactivate each other. Am J Resp Cell Mol Biol 1995: 12: 351-357.
169. ZHU Q, SOLOMON S. Isolation and mode of action of rabbit corticostatic (antiadrenocorticotropin) peptides. Endocrinology 1992: 130: 1413-1423.
170. SMITH EM, BROSNAN P, MEYER WJ, BLALOCK JE. An ACTH receptor on human mononuclear leukocytes. N Engl J Med 1987: 317: 1266-1269.
171. MIYASAKI KT, BODEAU AL. Human neutrophil azurocidin synergizes with leukocyte elastase and Cathepsin G in the killing of Capnocytophaga sputigena. Infect Immun 1992: 60: 4973-4975.
172. LEHRER RI, SZKLAREK D, GANZ T, SELSTED ME. Synergistic activity of rabbit granulocyte peptides against Candida albicans. Infec Immun 1986: 52: 902-904.
173. ELLISON RT, GIEHL TJ. Killing of Gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 1991: 88: 1080-1091.
174. LEHRER RI, GANZ T, SZKLAREK D, SELSTED ME. Modulation of the in vitro candidacidal activity of human neutrophil defensins by target cell metabolism and divalent cations. J Clin Invest 1988: 81: 1829-1835.
175. AKIN DT, LU MQ, LU SJ, KENDALL S, RUNDEGREN J, ARNOLD RR. Bactericidal activity of different forms of lactoferrin. In: HUTCHENS TW, RUMBALL SV, LONNERDAL B, eds. Lactoferrin: Structure and Function. Advances in Experimental Medicine & Biology, vol. 357. New York: Plenum Press: 1994: 61-70.
176. LEHRER RI, LICHTENSTEIN AK, GANZ T. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol 1993: 11: 105-128.
177. MACHNICKI M, ZIMECKI M, ZAGULSKI T. Lactoferrin regulates the release of tumor necrosis factor-alpha and interleukin-6 in vivo. Int J Exp Path 74: 433-439.